Ascent enhances the value of therapeutic products by establishing pathways that make the optimal integration of Japan and China into global drug development possible.
Ascent’s services allow emerging biopharma to independently attain key development milestones in Asia and retain the resulting value inflection rather than sacrificing it to licensing partners. Ascent provides both short-term consulting in support of rapid out-licensing deals and comprehensive regulatory and clinical development in support of larger scale strategic/commercial goals in the region.